Amy Dyken, controller at Pharoah Pharmaceutical Industries, a public company, is currently preparing the calculation for basic and diluted earnings per share and the related disclosure for Pharoah's financial statements. Below is selected financial information for the fiscal year ended June 30, 2020. Long-term debt Notes payable, 10% 8% convertible bonds payable 10% bonds payable Total long-term debt Shareholders' equity Pharoah Pharmaceutical Industries Selected Balance Sheet Information June 30, 2020 $1,020,000 4,970,000 5,940,000 $11,930,000 Preferred stock, 7% cumulative, $50 par value, 101,000 shares authorized, 25,250 shares issued and outstanding $1,262,500 Common stock, $1 par, 10,100,000 shares authorized, 1,010,000 shares issued and outstanding 1,010,000 Additional paid-in capital 3,950,000 Retained earnings Total shareholders' equity 6,110,000 $12,332,500